ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.605
      -0.21%
      Bitcoin
      65,131.36
      -0.01%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. AbbVie Inc (ABBV)

      7. AbbVie Inc (ABBV) News

      ABBV

      AbbVie (ABBV)

      AbbVie Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:ABBV
      DateTimeSourceHeadlineSymbolCompany
      11/01/20238:45AMPR Newswire (US)BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never BeforeNYSE:ABBVAbbVie Inc
      10/30/20238:00AMGlobeNewswire Inc.NEXGEL Secures Supply Agreement with AbbVieNYSE:ABBVAbbVie Inc
      10/27/20238:16AMDow Jones NewsAbbVie Raises Quarterly Dividend by 4.7% to $1.55NYSE:ABBVAbbVie Inc
      10/27/20237:49AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
      10/27/20237:38AMPR Newswire (US)AbbVie Reports Third-Quarter 2023 Financial ResultsNYSE:ABBVAbbVie Inc
      10/27/20237:10AMIH Market NewsFriday’s Wall Street Highlights: Enphase Energy, GM, Intel, Sanofi, Masimo, and moreNYSE:ABBVAbbVie Inc
      10/24/20238:30AMPR Newswire (US)Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar LinesNYSE:ABBVAbbVie Inc
      10/19/20235:06PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      10/19/20235:04PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      10/19/20238:45AMPR Newswire (US)Allergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom ProjectNYSE:ABBVAbbVie Inc
      10/17/20237:05AMPR Newswire (Canada)AbbVie's RINVOQ® (upadacitinib) Receives Health Canada Approval as the First and Only Oral Therapy for the Treatment of Adults with Moderately to Severely Active Crohn's DiseaseNYSE:ABBVAbbVie Inc
      10/17/20237:05AMPR Newswire (Canada)AbbVie reçoit l'approbation de Santé Canada pour l'emploi de RINVOQ® (upadacitinib) en tant que premier et seul traitement à administration orale destiné aux adultes atteints de la maladie de Crohn modérément à fortement évolutiveNYSE:ABBVAbbVie Inc
      10/17/20237:00AMPR Newswire (Canada)AbbVie's EPKINLY™ (epcoritamab injection/epcoritamab for injection) Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell LymphNYSE:ABBVAbbVie Inc
      10/17/20237:00AMPR Newswire (Canada)AbbVie obtient une autorisation de mise en marché avec conditions de Santé Canada pour EPKINLY (MC) (epcoritamab injectable/epcoritamab pour injection), le premier et le seul anticorps bispécifique administré par voie sous-cutanée et destiné au traitNYSE:ABBVAbbVie Inc
      10/15/202311:15AMPR Newswire (US)AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary EndpointsNYSE:ABBVAbbVie Inc
      10/12/20235:17PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
      10/12/20236:29AMDow Jones NewsAbbVie Advancing Rinvoq to Phase 3 Studies in VitiligoNYSE:ABBVAbbVie Inc
      10/12/20235:25AMPR Newswire (US)AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3NYSE:ABBVAbbVie Inc
      10/11/20238:30AMPR Newswire (US)AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic DermatitisNYSE:ABBVAbbVie Inc
      10/10/20238:45AMPR Newswire (US)AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023NYSE:ABBVAbbVie Inc
      10/05/20238:53AMDow Jones NewsAbbVie Exercises Right to Buy Biotech Mitokinin for Initial $110 MillionNYSE:ABBVAbbVie Inc
      10/05/20238:05AMPR Newswire (US)AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience PipelineNYSE:ABBVAbbVie Inc
      10/04/20234:11PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
      10/04/202311:07AMPR Newswire (US)Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer ImmunotherapyNYSE:ABBVAbbVie Inc
      10/04/20238:00AMPR Newswire (US)AbbVie to Host Third-Quarter 2023 Earnings Conference CallNYSE:ABBVAbbVie Inc
      10/03/20237:00AMPR Newswire (US)Allergan Aesthetics and Girls Inc. Partner to Speed the Entry of Young Women into Positions of Leadership in the STEM FieldNYSE:ABBVAbbVie Inc
      09/29/20238:15AMDow Jones NewsAbbVie: Phase 3 Venetoclax/Dexamethasone Study Falls Short in Multiple MyelomaNYSE:ABBVAbbVie Inc
      09/29/20237:15AMPR Newswire (US)AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple MyelomaNYSE:ABBVAbbVie Inc
      09/25/20238:50AMDow Jones NewsAbbVie, Genmab Get Conditional Europe OK of Tepkinly Lymphoma DrugNYSE:ABBVAbbVie Inc
      09/25/20237:45AMPR Newswire (US)AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell LymphomaNYSE:ABBVAbbVie Inc
       Showing the most relevant articles for your search:NYSE:ABBV